Operating Lease, Right-of-Use Asset of Akebia Therapeutics, Inc. from 31 Mar 2019 to 31 Dec 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of lessee's right to use underlying asset under operating lease.
Summary
Akebia Therapeutics, Inc. quarterly Operating Lease, Right-of-Use Asset in USD history and change rate from 31 Mar 2019 to 31 Dec 2025.
  • Akebia Therapeutics, Inc. Operating Lease, Right-of-Use Asset for the quarter ending 31 Dec 2025 was $3,663,000, a 55% decline year-over-year.
Source SEC data
View on sec.gov
Operating Lease, Right-of-Use Asset, Quarterly (USD)
Operating Lease, Right-of-Use Asset, YoY Quarterly Change (%)

Akebia Therapeutics, Inc. Quarterly Operating Lease, Right-of-Use Asset (USD)

Period Value YoY Chg Change % Date Report Filed Fiscal Year Fiscal Period
Q4 2025 $3,663,000 -$4,555,000 -55% 31 Dec 2025 10-K 26 Feb 2026 2025 FY
Q3 2025 $4,837,000 -$4,463,000 -48% 30 Sep 2025 10-Q 10 Nov 2025 2025 Q3
Q2 2025 $5,987,000 -$4,373,000 -42% 30 Jun 2025 10-Q 07 Aug 2025 2025 Q2
Q1 2025 $7,114,000 -$4,285,000 -38% 31 Mar 2025 10-Q 08 May 2025 2025 Q1
Q4 2024 $8,218,000 -$4,198,000 -34% 31 Dec 2024 10-K 26 Feb 2026 2025 FY
Q3 2024 $9,300,000 -$4,114,000 -31% 30 Sep 2024 10-Q 07 Nov 2024 2024 Q3
Q2 2024 $10,360,000 -$4,031,000 -28% 30 Jun 2024 10-Q 08 Aug 2024 2024 Q2
Q1 2024 $11,399,000 -$16,559,000 -59% 31 Mar 2024 10-Q 09 May 2024 2024 Q1
Q4 2023 $12,416,000 -$16,742,000 -57% 31 Dec 2023 10-K 13 Mar 2025 2024 FY
Q3 2023 $13,414,000 -$16,923,000 -56% 30 Sep 2023 10-Q 08 Nov 2023 2023 Q3
Q2 2023 $14,391,000 -$17,103,000 -54% 30 Jun 2023 10-Q 28 Aug 2023 2023 Q2
Q1 2023 $27,958,000 -$4,673,000 -14% 31 Mar 2023 10-Q 08 May 2023 2023 Q1
Q4 2022 $29,158,000 -$4,694,000 -14% 31 Dec 2022 10-K 14 Mar 2024 2023 FY
Q3 2022 $30,337,000 +$7,145,000 +31% 30 Sep 2022 10-Q 03 Nov 2022 2022 Q3
Q2 2022 $31,494,000 +$7,052,000 +29% 30 Jun 2022 10-Q 04 Aug 2022 2022 Q2
Q1 2022 $32,631,000 +$6,961,000 +27% 31 Mar 2022 10-Q 09 May 2022 2022 Q1
Q4 2021 $33,852,000 +$6,976,000 +26% 31 Dec 2021 10-K/A 28 Aug 2023 2022 FY
Q3 2021 $23,192,000 -$2,529,000 -9.8% 30 Sep 2021 10-Q 04 Nov 2021 2021 Q3
Q2 2021 $24,442,000 -$2,442,000 -9.1% 30 Jun 2021 10-Q 05 Aug 2021 2021 Q2
Q1 2021 $25,670,000 -$2,356,000 -8.4% 31 Mar 2021 10-Q 10 May 2021 2021 Q1
Q4 2020 $26,876,000 -$2,162,000 -7.4% 31 Dec 2020 10-K 01 Mar 2022 2021 FY
Q3 2020 $25,721,000 -$4,420,000 -15% 30 Sep 2020 10-Q 05 Nov 2020 2020 Q3
Q2 2020 $26,884,000 -$4,340,000 -14% 30 Jun 2020 10-Q 10 Aug 2020 2020 Q2
Q1 2020 $28,026,000 -$4,373,000 -13% 31 Mar 2020 10-Q 05 May 2020 2020 Q1
Q4 2019 $29,038,000 31 Dec 2019 10-K 25 Feb 2021 2020 FY
Q3 2019 $30,141,000 30 Sep 2019 10-Q 12 Nov 2019 2019 Q3
Q2 2019 $31,224,000 30 Jun 2019 10-Q 08 Aug 2019 2019 Q2
Q1 2019 $32,399,000 31 Mar 2019 10-Q 09 May 2019 2019 Q1
* An asterisk sign (*) next to the value indicates that the value is likely invalid.